<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657342</url>
  </required_header>
  <id_info>
    <org_study_id>BT - L-CsA - 301 - SLT</org_study_id>
    <nct_id>NCT03657342</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A Inhalation Solution in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplant</brief_title>
  <acronym>BOSTON-1</acronym>
  <official_title>A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered Via the PARI Investigational eFlow® Device Plus Standard of Care Versus Standard of Care Alone in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III randomized, controlled clinical trial of L-CsA for the treatment of
      bronchiolitis obliterans syndrome in adults diagnosed with BOS following single lung
      transplant. Patients will receive either L-CsA (5 mg) via the PARI Investigational eFlow®
      Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48
      weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA
      following completion of BOSTON-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regardless of treatment allocation, all patients will continue to receive their SoC regimen
      for maintenance of the lung allograft. Eligible patients for the clinical trial must have a
      tacrolimus-based triple-drug therapy in combination with mycophenolate mofetil or its
      equivalent and a corticosteroid.

      A total of 11 visits will be performed during the clinical trial. After informed consent has
      been obtained, a Screening Visit will be carried out in order to check general eligibility
      for participation. At the Randomization Visit, inclusion and exclusion criteria will be
      re-checked and spirometry performed. During the 48-week treatment period, visits are
      scheduled every 4-8 weeks. If a patient has an event that meets one of the criteria for
      progression of BOS, he/she will return to the clinic within 2-weeks for an unscheduled visit
      to have spirometry and other procedures performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in FEV1 (mL) from baseline to Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in FEV1/FVC from baseline to Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression of BOS</measure>
    <time_frame>From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>defined as the earliest of the following:
Absolute decrease from baseline in FEV1 &gt;/= 10% or &gt;/= 200 mL and absolute decrease in FEV1/FVC of &gt; 5% OR
Change in BOS Severity, OR
Re-transplantation, OR
Death from respiratory failure This endpoint will be assessed in a combined analysis with a similar Phase III clinical trial, BT - L-CsA - 302 - DLT (BOSTON-2) which will be conducted in the same investigational centers in patients who have undergone double-lung transplantations.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline through study completion (52 weeks)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Acute tolerability of L-CsA</measure>
    <time_frame>Baseline through Week 48</time_frame>
    <description>change in forced expiratory volume in one second (FEV1); reports of cough or shortness of breath</description>
  </other_outcome>
  <other_outcome>
    <measure>Hematology and Serum Chemistry Parameters</measure>
    <time_frame>From date of randomization until end of study participation (52 weeks)</time_frame>
    <description>Number of patients with treatment-related changes in hematology or serum chemistry parameters assessed by CTCAE v5.0.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>Chronic Rejection of Lung Transplant</condition>
  <condition>Lung Transplant Rejection</condition>
  <condition>Lung Transplant; Complications</condition>
  <condition>Lung Transplant Failure and Rejection</condition>
  <arm_group>
    <arm_group_label>L-CsA treatment plus SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-CsA 5 mg twice daily for 48 weeks Standard of Care Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Cyclosporine A</intervention_name>
    <description>delivered via the PARI eFlow® Device</description>
    <arm_group_label>L-CsA treatment plus SoC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients ≥ 18 years who received a single lung transplant at least 12 months
             prior to Screening.

          2. Patients with clinically defined BOS (CLAD - BOS phenotype) with screening FEV1
             between 85-60% of personal best FEV1 value post-transplant.

          3. Patients with an FEV1/FVC ratio of &lt;/= 0.7.

          4. Patients in whom the diagnosis of BOS has been confirmed by the elimination of other
             possible causes of obstructive lung disease.

          5. Patients with a diagnosis of BOS made at least 1 year after transplant surgery and
             within 12 months prior to the Screening Visit.

          6. Patients should be on a three-drug maintenance regimen of immunosuppressive agents
             including tacrolimus, a second agent such as but not limited to MMF or azathioprine,
             and a systemic corticosteroid such as prednisone. The regimen must be stable for at
             least 4-weeks prior to Randomization with respect to the therapeutic agents.

          7. Patients must consent to retrieve prespecified data from the historic medical record
             (e.g., information related to the transplant surgery; spirometry data; medication
             use).

          8. Patients must be receiving or have received post-transplant prophylaxis against
             Cytomegalovirus (CMV) and Pneumocystis pneumonia as per SoC at the site.

          9. Patients capable of understanding the purposes and risks of the clinical trial, who
             have given written informed consent and agree to comply with the clinical trial
             requirements/visit schedules, and who are capable of aerosol inhalation.

         10. Women of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days prior to randomization and must agree to use one of the methods of
             contraception listed in Appendix II of the protocol through their End of Study Visit.

         11. Patients have no concomitant diagnoses that are considered fatal within one year (12
             months) of Screening.

        Exclusion Criteria:

          1. Patients with confirmed other causes for loss of lung function, such as acute
             infection, acute rejection, restrictive allograft syndrome (RAS), etc.

          2. Patients with Cystic Fibrosis.

          3. Patients with acute antibody-mediated rejection at Screening. In this context,
             clinically stable patients displaying low and stable levels of donor-specific
             antibodies (DSA) at the Screening Visit (as judged by the Investigator) are eligible
             for the study.

          4. Active acute bacterial, viral, or fungal infection not successfully resolved at least
             4 weeks prior to the Screening Visit. Patients with chronic infection or colonization
             who are clinically stable as per judgement of the Investigator are eligible for the
             study.

          5. Mechanical ventilation within 12 weeks prior to Randomization.

          6. Patients with uncontrolled hypertension.

          7. Patient has baseline resting oxygen saturation of &lt; 89% on room air or use of
             supplemental oxygen.

          8. Evidence of functional airway stenosis (e.g., bronchomalacia/tracheomalacia, airway
             stents, or airways requiring balloon dilatations to maintain patency) with onset after
             the initial diagnosis of BOS and ongoing at Screening and/or Randomization Visit.

          9. Known hypersensitivity to L-CsA or to cyclosporine A.

         10. Patients with chronic renal failure, defined as serum creatinine &gt; 2.5 mg/dL, or
             requiring chronic dialysis.

         11. Patients with liver disease and serum bilirubin &gt; 3-fold upper limit of normal range
             or transaminases &gt; 2.5 upper limit of normal range.

         12. Patients with active malignancy within the previous 2 years, including post-transplant
             lymphoproliferative disorder, with the exception of treated, localized basal and
             squamous cell carcinomas.

         13. Pregnant women or women who are unwilling to use appropriate birth control to avoid
             pregnancy through their End of Study Visit.

         14. Women who are currently breastfeeding.

         15. Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to
             the Screening Visit. This is defined as any treatment that is implemented under an
             Investigational New Drug (IND) or compassionate use.

         16. Patients who have received extracorporeal photophoresis (ECP) for treatment of BOS
             within 1 month prior to Randomization.

         17. Patients who are currently participating in an interventional clinical trial.

         18. Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary procedures.

         19. Any co-existing medical condition that in the Investigator's judgment will
             substantially increase the risk associated with the patient's participation in the
             clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noreen R Henig, MD</last_name>
    <role>Study Director</role>
    <affiliation>Breath Therapeutics, Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammy Abuan, RN, MS</last_name>
    <phone>+1.650.272.0655</phone>
    <email>tammy.abuan@zambongroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramachandra Sista, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajat Walia, MD</last_name>
      <email>rajat.walia@dignityhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Weigt, MD</last_name>
      <email>sweigt@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gundeep Dhillon, MD</last_name>
      <email>gdhillon@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hays, MD</last_name>
      <email>steven.hays@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Pelaez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si Pham, MD</last_name>
      <email>pham.si@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chadi Hage, MD</last_name>
      <email>chage@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Albert B. Chandler Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maher Baz, MD</last_name>
      <email>maher.baz@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartley Griffith, MD</last_name>
      <email>bgriffith@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pali Shah, MD</last_name>
      <email>pdedhiy2@jymi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramsey Hachem, MD</last_name>
      <email>rhachem@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selim Arcasoy, MD</last_name>
      <email>sa2059@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Reynolds, MD</last_name>
      <email>john.reynolds@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Budev, DO</last_name>
      <email>budevm@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Keller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Crespo, MD</last_name>
      <email>maria.crespo@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Criner, MD</last_name>
      <email>gerard.criner@tuhs.temple.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Pilewski, MD</last_name>
      <email>pilewskijm@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chetan Naik, MD</last_name>
      <email>chetan.naik@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Huang, MD</last_name>
      <email>hjhuang@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shambhu Aryal, MD</last_name>
      <email>shambhu.aryal@inova.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Kessler, MD</last_name>
      <email>romain.kessler@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Gottlieb, MD</last_name>
      <email>gottlieb.jens@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum Großhadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Behr, MD</last_name>
      <email>juergen.behr@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mordechai Kramer, MD</last_name>
      <email>kramerm@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Monforte, MD</last_name>
      <email>vmonforte@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de A Coruna</name>
      <address>
        <city>Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes De la Torre, MD</last_name>
      <email>mercedes.de.la.torre.bravos@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reina Sofia University Hospital</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Redel-Montero, MD</last_name>
      <email>javierredel@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. U. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia de Pablo Gafas, MD</last_name>
      <email>alic1575@separ.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piedad Ussetti, MD</last_name>
      <email>pussetti.hpth@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Cifrian, MD</last_name>
      <email>josemanuel.cifrian@scsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital LA F3</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Sole, MD</last_name>
      <email>sole_amparo@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jasvir Parmar, MD</last_name>
      <email>jas.parmar@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Al-Aloul, MD</last_name>
      <email>mohamed.alaloul@mft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

